Want to see CAPR full AI Analyst Report?
CAPR Stock Chart & Stats
$8.29
-$12.67(-64.31%)
At close: 4:00 PM EDT
$8.29
-$12.67(-64.31%)
Day’s Range― - ―
52-Week Range$2.96 - $40.37
Previous CloseN/A
Volume8.05M
Average Volume (3M)10.69M
Market Cap
$576.16M
Enterprise Value$1.25K
Total Cash (Recent Filing)$237.93M
Total Debt (Recent Filing)$91.05M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Nov 17, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding58,138,990
10 Day Avg. Volume10,492,898
30 Day Avg. Volume10,692,284
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.39
Price to Sales (P/S)0.00
P/FCF Ratio-18.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$23.80Price Target Upside187.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.55
Revenue Forecast (FY)$91.62M
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 EfficacyThe statistically significant primary endpoint supports deramiocel’s potential to preserve upper-limb function in DMD, a clinically meaningful outcome that may underpin a focused approval and provide a durable foundation for commercialization.
Peer-reviewed Clinical ValidationPublication in a leading peer-reviewed journal adds independent visibility and credibility to the pivotal dataset. This can strengthen confidence among regulators, clinicians and potential commercial partners as Capricor advances its lead program.
Established Safety And Manufacturing ReadinessBroad clinical exposure and long-term treatment experience provide a substantial safety database for a cell therapy. Operational in-house GMP capacity also improves control over manufacturing and could support a launch if regulatory approval is obtained.
Bears Say
FDA Review Delay And Regulatory UncertaintyThe three-month review extension delays potential commercialization and indicates that the amendment requires substantial additional FDA evaluation. This prolongs uncertainty around approval timing, launch planning and the company’s path to recurring product revenue.
No Revenue And Widening LossesCapricor remains pre-commercial, with no reported revenue and materially higher expenses and losses. Until a product is approved and launched, continued development and launch spending will keep profitability absent and increase dependence on external financing.
Limited Support For Cardiomyopathy IndicationThe negative non-binding vote weakens the case for the originally targeted cardiomyopathy indication and may narrow the initial commercial opportunity. It also raises approval and labeling risk despite the stronger upper-limb primary endpoint.
Capricor Therapeutics News
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $2.96 and its highest was $40.37 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is $576.16M.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 75 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.589 by -$0.111.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 58,138,990 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.589. Following the earnings report the stock price went up 57.957%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in CAPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.80 (187.09% Upside)
$23.80 (187.09% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 83%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 14.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 16.5%
Last 30 Days ▲ 16.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
59.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
176.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
CAPR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful clinical and regulatory progress (Lancet publication, statistically significant primary HOPE‑3 endpoint for upper limb function, established safety exposure, operational in‑house manufacturing and $237.9M cash) against substantial near‑term challenges (AdCom vote against the cardiomyopathy question, mixed secondary endpoint results, no revenue, rising operating expenses and widening losses, a Form 483 observation, paused non‑Daramycin pipeline work, and an ongoing commercial dispute with NS Pharma). Management has a clear path to submit an amendment focused on the primary skeletal muscle indication and the FDA indicated willingness to review it, but regulatory and financial risks remain in the near term.View all CAPR earnings summariesCAPR Stock 12 Month Forecast
Average Price Target
$23.80
▲(187.09% Upside)
Technical Analysis
Ownership Overview
0.93% Insiders
8.15% Mutual Funds
31.74% Other Institutional Investors
45.93% Public Companies and
Individual Investors